AI and evolving regulations set to transform biopharma operations in drug development and quality.
Rik van Mol, Veeva Systems
Over recent years, biopharmaceutical companies have made significant strides in linking data and processes across clinical, regulatory, safety, and quality functions. In 2026, the operational focus will shift further toward seamless flow: connected activity across teams supported by a robust technology infrastructure that enhances visibility, traceability, and inspection readiness. This push comes as European regulatory expectations continue to evolve. In parallel, AI will mature from early-stage capability to embedded, compliant systems. Below are four predictions for where the biopharmaceutical industry is headed in 2026.
European Regulation Drives “Inspection-Ready by Design”
In 2026, regulatory change in Europe will feel less like a series of one-off milestones and more like a steady operating reality. Clinical teams will be firmly in a clinical trials information system (CTIS)-first world under the EU Clinical Trials Regulation, which continues to raise expectations for consistency across countries, faster coordination, and complete, traceable documentation. Coupled with moves toward structured submissions such as electronic common technical document (eCTD) 4.0, this requires organizations to move beyond ad-hoc fixes and to deliver consistent quality every time, with fewer exceptions and moving beyond the need for local workarounds or fixes.
Read more with free registration
Register now for free and get full access to all exclusive articles from chemanager-online.com. With our newsletter we regularly send you top news from the chemistry industry as well as the latest e-issue.
most read
20 Years of CHEManager International
Incredible but true: CHEManager International is celebrating its 20th anniversary!
Relocation of Chemicals Production Footprint in Full Swing
A new Horváth study based on interviews with CxOs of Europe’s top chemical corporations reveals: The majority of board members expects no or only weak growth for the current year.
US Tariffs Fatal for European Pharma
Trump's tariff policy is a considerable burden and a break with previous practice.
Q1 2025 Chemical Industry: Diverging Trends
The first quarter of 2025 highlights a continued divergence between the European and US chemical industries.
Lead or Lag: Europe’s AI Materials Race
How AI and Robotics are reshaping the race for materials discovery.